P
0.912
0.01 (1.52%)
| Penutupan Terdahulu | 0.899 |
| Buka | 0.903 |
| Jumlah Dagangan | 319,686 |
| Purata Dagangan (3B) | 417,793 |
| Modal Pasaran | 56,497,540 |
| Harga / Buku (P/B) | 0.470 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2026 |
| EPS Cair (TTM) | -3.61 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 23.40% |
| Nisbah Semasa (MRQ) | 11.03 |
| Aliran Tunai Operasi (OCF TTM) | -174.10 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -112.84 M |
| Pulangan Atas Aset (ROA TTM) | -33.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -63.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Pliant Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 0.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.0 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.24 |
|
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.04% |
| % Dimiliki oleh Institusi | 95.97% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |